Vaccines alone are not enough, a model shows. And if precautions like working remotely, limiting travel and wearing masks are relaxed too soon, it could mean millions more infections and thousands more deaths.
Vaccines alone will not end the pandemic, Columbia University model shows mcall.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mcall.com Daily Mail and Mail on Sunday newspapers.
Wednesday, 27 January 2021, 7:53 am
26 January 2021 – Important advances in HIV prevention
research were announced today at the 4th
HIV Research for Prevention Conference (HIVR4P //
Virtual), convened by IAS – the International AIDS
Society.
Highlights included findings from a pair of
trials evaluating whether infusions with a broadly
neutralizing antibody (bNAb) can prevent HIV acquisition and
positive interim results from a study of long-acting
injectable pre-exposure prophylaxis (PrEP) in women. Other
announcements included promising data from a study of
islatravir as a once-monthly PrEP pill, a study warning that
many African countries are not on track to meet key UNAIDS
prevention targets, new data on global uptake of PrEP, and a
For the first time, researchers say infusions of antibodies can prevent HIV infection Source:
Corey L, et al. Abstract 1480. Presented at: HIV Research for Prevention; Jan. 27-28 and Feb. 3-4, 2021 (virtual meeting). Disclosures: Fauci reports no relevant financial disclosures. Healio could not confirm financial disclosures for Corey or Mgodi at the time of publishing. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Science’
s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
News from U.S. manufacturer Moderna that its COVID-19 vaccine is still “expected to be protective” against a virus variant first detected in South Africa came as a relief to scientists and the public. But the 25 January announcement included a caveat: Antibodies triggered by the vaccine appear to be a little less potent against the new variant, named B.1.351, than the one the vaccine was developed for. So researchers were perhaps even more relieved to hear the company will start development of booster shots tailored to B.1.351 and other variants.